Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2005 Apr;7(2):151-6.

Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.

Author information

National Institutes of Health, National Cancer Institute-Frederick, Center for Cancer Research, Laboratory of Experimental and Computational Biology, Protein Interactions Group, Frederick, MD 21702-1201, USA.


Polyclonal antibodies have a century-old history of being effective against some viruses and, recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human mAbs to the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein have been developed by several research groups at an amazing pace. These antibodies potently neutralize infectious virus in tissue cultures and animal models, and, alone or in combination with vaccines and other drugs, may have potential for the prevention and treatment of SARS.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center